JNJ vs DXCM
By Alex · Tickerpine
Johnson & Johnson vs DexCom, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | DXCM |
|---|---|---|
| Price | $271.22 | $86.62 |
| Market cap | $653.61B | $32.69B |
| P/E ratio | 31.5 | 34.2 |
| ROE | 25.74% | 38.49% |
| Profit margin | 21.48% | 20.12% |
| Revenue growth | 6.60% | 13.10% |
| Dividend yield | 1.98% | — |
| Beta | 0.23 | 1.42 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs DXCM in plain English
- JNJ is the bigger company — about 20.0× the market cap of DXCM.
- JNJ is cheaper on earnings (P/E 31.5 vs 34.2).
- DXCM earns a higher return on equity (38% vs 26%).
- DXCM is growing revenue faster (13% vs 7%).
- JNJ pays a dividend (1.98%) while the other effectively doesn't.
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
DXCM return calculator
See what $1,000 in DexCom, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.